Specification Strength/ Size Packing Size Packed In Malaria Antigen PF/ PV Card Test 50 Tests 50 Box Pack Malaria Antibody PF/ PV Card Test 50 Tests 50 Box Pack
Specification Strength/ Size Packing Size Packed In Syphilis Test Card 50 Tests 50 Box Pack
Specification Strength/ Size Packing Size Packed In Typhoid IgG/IgM 50 Tests 50 Box Pack
Specification Strength/ Size Packing Size Packed In HCG Mini Card 50 Tests 50 Box Pack
Specification Strength/ Size Packing Size Packed In HCG Mini Card 50 Tests 50 Box Pack HCG Big Card 50 Tests 50 Box Pack
Specification Strength/ Size Packing Size Packed In HCG Test Strip (Dipstick) 50 Tests 50 Box Pack
Specification Strength/ Size Packing Size Packed In Reagent Strip for detection of Albumin & Glucose in Urine 100 Tests 100 Box Pack
Specification Strength/ Size Packing Size Packed In HCV Test Cards 10 Card Test Per Pack 50 Box Pack
Specification Strength/ Size Packing Size Packed In Dengue Test 50 Card Test Per Pack 10 Box Pack
Specification Strength/ Size Packing Size Packed In Glucose Test Bottle of 100T
Specification Strength/ Size Packing Size Packed In Protein Test Bottle of 100T
Specification Strength/ Size Packing Size Packed In Glucose, Bilirubin, Ketone, Specific Gravity, Blood, pH, Protein, Urobilinogen, Nitrite and Leukocytes Bottle of 100T
Molecular Diagnostic Tests for SARS-CoV-2 Other Tests for SARS-CoV-2 Serology and Other Adaptive Immune Response Tests for SARS-CoV-2 IVDs for Management of COVID-19 Patients
RNA Extraction Kit
Dengue Combo
Malaria Antigen Kit
Pap Smear Kit
HBS AG
HCV Test Kit
DiaPlexQ Novel Coronavirus (2019-nCoV) Detection Kit Real-Time OneStep RT-PCR based assay system for detection of SARS-CoV-2 [Product Approval] U.S FDA EUA, Health Canada IO, CE-IVD marked The DiaPlexQ Novel Coronavirus (2019-nCoV) Detection Kit is a real-time reverse transcriptase (RT)-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swabs, oropharyngeal (throat) swabs, anterior nasal swabs, mid-turbinate nasal swabs, nasal aspirates, nasal washes, bronchoalveolar lavage (BAL) fluid and sputum from individuals suspected of COVID-19 by their healthcare provider. Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. The agent detected may not be the definite cause of disease. Positive results do not rule out bacterial infection or co-infection with other viruses. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. The DiaPlexQ Novel Coronavirus (2019-nCoV) Detection Kit is intended for use by qualified clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures.
